635 related articles for article (PubMed ID: 27590328)
1. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors.
Firwana B; Ravilla R; Raval M; Hutchins L; Mahmoud F
J Oncol Pharm Pract; 2017 Dec; 23(8):620-624. PubMed ID: 27590328
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
[TBL] [Abstract][Full Text] [Related]
3. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
Tan I; Malinzak M; Salama AKS
J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
[TBL] [Abstract][Full Text] [Related]
4. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy-associated autoimmune hemolytic anemia.
Khan U; Ali F; Khurram MS; Zaka A; Hadid T
J Immunother Cancer; 2017; 5():15. PubMed ID: 28239468
[TBL] [Abstract][Full Text] [Related]
6. The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review.
Moujaess E; Haddad FG; Eid R; Kourie HR
Immunotherapy; 2019 Nov; 11(16):1409-1422. PubMed ID: 31621445
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.
Chanson N; Ramos-Casals M; Pundole X; Suijkerbuijk K; José de Barros E Silva M; Lidar M; Benesova K; Leipe J; Acar-Denizli N; Pradère P; Michot JM; Voisin AL; Suárez-Almazor ME; Radstake TRD; Fernandes Moça Trevisani V; Schulze-Koops H; Melin A; Robert C; Mariette X; Baughman RP; Lambotte O; ; ; ; ; ;
Eur J Cancer; 2021 Nov; 158():208-216. PubMed ID: 34452793
[TBL] [Abstract][Full Text] [Related]
9. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
10. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
11. Intralesional and systemic immunotherapy for metastatic melanoma.
Luu C; Khushalani NI; Zager JS
Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
[TBL] [Abstract][Full Text] [Related]
12. Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.
Reddy SB; Possick JD; Kluger HM; Galan A; Han D
J Immunother; 2017 Oct; 40(8):307-311. PubMed ID: 28737620
[TBL] [Abstract][Full Text] [Related]
13. Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission.
Yatim N; Mateus C; Charles P
Rev Med Interne; 2018 Feb; 39(2):130-133. PubMed ID: 29277453
[TBL] [Abstract][Full Text] [Related]
14. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
Kähler KC; Hassel JC; Heinzerling L; Loquai C; Thoms KM; Ugurel S; Zimmer L; Gutzmer R;
J Dtsch Dermatol Ges; 2020 Jun; 18(6):582-609. PubMed ID: 32489011
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis.
Lomax AJ; McGuire HM; McNeil C; Choi CJ; Hersey P; Karikios D; Shannon K; van Hal S; Carr U; Crotty A; Gupta SK; Hollingsworth J; Kim H; Fazekas de St Groth B; McGill N
Int J Rheum Dis; 2017 Sep; 20(9):1277-1285. PubMed ID: 28480561
[TBL] [Abstract][Full Text] [Related]
16. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
17. A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors.
Levine O; Devji T; Xie F
Hum Vaccin Immunother; 2017 Aug; 13(8):1765-1767. PubMed ID: 28481695
[TBL] [Abstract][Full Text] [Related]
18. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
20. Predictors of immunotherapy-induced immune-related adverse events.
Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
